Long life and mental health biotech companies take note: Korify Capital is putting together a $100 million investment fund targeting your space and looking to build a portfolio of 15-20 companies across Europe, the United States, and Israel.
The $100 million target investment vehicle, which is expected to close in the middle of next year, is the first Curifi Fund, the international investment arm of Swiss family office Infinitas Capital. Infinitas is active in multiple areas outside of biotechnology, particularly real estate, but has been following developments in aging and mental health research and has decided the time is right to enter this field.
“There is a lot of opportunity coming from academia. We have made a lot of progress in research that we now hope will translate to human applications in the coming years, we have made great progress on the animal front and we can really do a lot more,” said Robin Lauber, co-founder and chairman of the board. Infinitas, “They really extend their life.”
Lauber and David Ottolini, co-founder of Korify, each identify COVID-19 as an accelerator, because it has fueled public investor interest in longevity and because it can spur innovation in the historically moribund mental health sector. With large biopharma companies withdrawing from CNS research, Corivy sees room for smaller biotech to build on academic advancements, creating investment opportunities for a new venture capital fund.
Related: Cambrian stalls $100M for 14 assets, 3-5 trials in 18 months
“There is no such thing as two dominant companies that only own the space,” Lauber said. “Instead, there’s a lot of disruption happening on a smaller scale, in smaller biotech companies, which are very profitable to invest in and very interesting from an investor’s perspective.”
Korify plans to invest in 15 to 20 of these critical technologies, with a focus on platform companies in later stages. This focus is evidenced by Korify’s decision to make Cambrian Biopharma its number one investment. Cambrian, which came out of stealth in February, has revealed $160 million in funding this year to advance a pipeline of 14 candidate drugs designed to target biological drivers of aging.
“We love their style of being so versatile, with multiple shots on multiple targets,” Lauber said. They are also well aware of the current regulatory systems in place. We don’t have any strong biomarkers for longevity, so their strategy is set up in such a way that they can get there with the current FDA framework.”